300 mg double-blinded secukinumab ( DrugBank: Secukinumab )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
271	強直性脊椎炎	1

271. 強直性脊椎炎

---

臨床試験数 : 563 /  薬物数 : 372 - (DrugBank : 72) / 標的遺伝子数 : 41 - 標的パスウェイ数 : 145

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03350815 (ClinicalTrials.gov)	March 13, 2018	31/10/2017	Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis	A Randomized, Double-blind, Parallel-group, Multicenter Study of Secukinumab to Compare 300 mg and 150 mg at Week 52 in Patients With Ankylosing Spondylitis Who Are Randomized to Dose Escalation After Not Achieving Inactive Disease During an Initial 16 Weeks of Open-label Treatment With Secukinumab 150 mg (ASLeap)	Ankylosing Spondylitis	Drug: 150 mg open-label secukinumab;Drug: 150 mg double-blinded secukinumab;Drug: 300 mg double-blinded secukinumab	Novartis Pharmaceuticals	NULL	Completed	18 Years	N/A	All	323	Phase 4	United States